News

Adherence to a Mediterranean diet is associated with improved musculoskeletal health and fewer falls, according to study data presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting held earlier this month.

Low-dose oral glucocorticoid therapy increases only vertebral fracture risk in rheumatoid arthritis patients, a study shows.

Findings indicate placebo responses are more than a psychological placebo effect.

An expert discusses the difficulties in diagnosing and managing myositis, as well as how the COVID-19 pandemic has affected clinical care.

Low levels of osteocalcin are associated with an increased risk of diabetes in patients treated with glucocorticoids, according to a study presented on Sept. 11 at the American Society for Bone and Mineral Research (ASBMR) annual meeting which wrapped this week as a virtual meeting.

Improving vitamin D status might decrease the risk of developing severe respiratory distress and death in COVID-19 cases, shows an observational study presented September 11 at the American Society for Bone and Mineral Research (ASBMR) which was held virtually this week.

Bisphosphonate use, especially for more than five years, is associated with an increased risk of atypical femoral fractures, but this risk falls considerably after discontinuation, according to a Nationwide Danish an analysis and review presented on September 13 at the American Society for Bone and Mineral Research (ASBMR) annual meeting which was held virtually.

Teriparatide, a recombinant human parathyroid hormone analog [rhPTH(1-34)] approved for women and men with osteoporosis, has been shown to renew bone tissue in patients with femoral neck fractures of the hip, according to research presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting which was held this week.

Some evidence shows the combination of teriparatide and denosumab, followed by a single dose of zoledronate, may be an effective strategy in the long-term management of high-risk fragility fractures.

Spending more time in high-intensity physical activity in early life may protect against osteoporosis in later life, and men are more successful at this than women, according to a study recently published in JAMA Network Open.

An expert discusses the state of screening, diagnosing, and treating osteoarthritis and osteoporosis.

Drug therapy appears to be the first-line option for reducing fracture risk in osteoporosis, but it is not always feasible, and increasing calcium, vitamin D and protein intake may be a more practical option.

High-dose vitamin D supplementation compared with standard-dose vitamin D supplementation resulted in a greater loss of volumetric bone mineral density in women but not men, according to study data presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting which is being held virtually.

Which composite measures detect the highest level of changes in psoriatic disease activity.

Three months of treatment with the osteoporosis drug abaloparatide (Tymlos, Radius) has a robust effect on bone formation in postmenopausal women with osteoporosis, according to a study presented on Sept. 12 at the American Society for Bone and Mineral Research (ASBMR) annual meeting which is being held virtually.

In the MONARCH OLE study, more than 50% of patients with rheumatoid arthritis who had low or inadequate response to adalimumab and switched to sarilumab experienced an improvement in disease activity.

Patient assessments measured fatigue, disease activity, global spinal pain, and spinal pain at night.

A majority of patients with the condition are on azathioprine or mycophenolate mofetil and mycophenolic acid.

These findings suggest the possibility of a common underlying disease process between the two pathologies.

Report shows that sarilumab may be better at controlling severe and refractory pain in rheumatoid arthritis patients than adalimumab.

The investigational JAK inhibitor filgotinib―which is under study as a treatment for a number of rheumatic diseases―has been shown to be safe and well tolerated in psoriatic arthritis patients.

Filgotinib was well-tolerated and sustained efficacy in a 52-week extension study.

A post-hoc analysis of 3 randomized controlled trials reports on the associations between the IL-6 inhibitor and unacceptable or refractory pain.

Other measures, like home oxygen dependency, all-cause mortality, and hospitalization for respiratory failures rates, had no apparent association with RF and/or ACPA status

The osteoporosis treatment abaloparatide has been shown to increase bone mineral density of the lumbar spine, total hip and femoral neck bone in patients with osteoporosis who are at high risk for fracture, according to a study presented today at the American Society for Bone and Mineral Research annual meeting which is being held virtually through Tuesday.

There were no new safety signals and efficacy was sustained through 156 weeks.

According to a poster presented at CCR East 2020, patients <60 and ≥60 years old achieved minimal disease activity and cDAPSA low disease or remission.

Early initiation following fragility fractures helps manage osteoporosis.

Treatment approaches for the management of secondary HLH is problematic due to the heterogeneity of approaches and rarity of the condition.

This is the first time such an algorithm was validated in a large US claims database.